Action of MDMA (Ecstasy) and its metabolites on arginine vasopressin release

Annals of the New York Academy of Sciences

Volumn 965, Issue , 2002, Pages 399-409

  Fallon, J K ^a   Shah, D ^b   Kicman, A T ^a   Hutt, A J ^a   Henry, J A ^c   Cowan, D A ^a   Forsling, M ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Arginine vasopressin; Ecstasy; MDMA

Indexed keywords

3 O METHYL ALPHA METHYLDOPAMINE; 3,4 DIHYDROXYAMPHETAMINE; 3,4 DIHYDROXYMETHAMPHETAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; ARGIPRESSIN; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; CONFERENCE PAPER; DRUG CAPSULE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; HORMONE RELEASE; HUMAN; HUMAN EXPERIMENT; HYPONATREMIA; HYPOTHALAMUS; MALE; METABOLITE; NONHUMAN; NORMAL HUMAN; RAT; VASOPRESSIN RELEASE;

ANIMALIA;

EID: 0036294852     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04181.x     Document Type: Conference Paper

References (50)

1. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy')
2. Ecstasy, 3-4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia
3. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy")
4. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse
5. Hyponatraemia and catatonic stupor after taking "ecstasy."
6. Hyponatraemia after ingestion of ecstasy
7. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "ecstasy" (3,4-MDMA)
8. Cerebral oedema after ingestion of MDMA ("ecstasy") and unrestricted intake of water
9. Hyponatraemia and death after "ecstasy" ingestion
10. Identification of metabolites of 3,4-(methylenedioxy)methamphetamine in human urine
11. Analysis of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS
12. Enantioselective determination of 3,4-methylene-dioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis
13. Pharmacology of MDMA in humans
14. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans
15. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6)
16. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6
17. Interactions of amphetamine analogs with human liver CYP2D6
18. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs
19. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
20. The configuration of α-methyldopamine
21. Alpha-methyldopamine derivatives. Synthesis and pharmacology
22. Demethyl analogues of psychoactive methoxyphenalkylamines: Synthesis and serotonin receptor affinities
23. Gas chromatographic/mass spectrometric assay for profiling the enantiomers of 3,4-methylenedioxymethamphetamine and its chiral metabolites using positive chemical ionization ion trap mass spectrometry
24. Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (Ecstasy) in humans
25. Daily patterns of secretion of neurohypophysial hormones in man: Effect of age
26. Pituitary and plasma vasopressin concentrations and fluid balance throughout the oestrous cycle of the rat
27. Acetylcholine and norepinephrine stimulate the release of corticotropin-releasing factor-41 from the rat hypothalamus in vitro
28. Melatonin and its analogs inhibit the basal and stimulated release of hypothalamic vasopressin and oxytocin in vitro
29. Low-dose MDMA ("ecstasy") induces vasopressin secretion
30. Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ('ecstasy'); is metabolism a contributory factor?
31. The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability
32. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): Pharmacology and toxicology in animals and humans
33. Fatal brain edema after ingestion of ecstasy and benzylpiperazine
34. Hyponatraemia at a rave
35. Acute hyponatraemiai
36. Hyponatraemia, seizures and stupor associated with ecstasy ingestion in a female
37. The natriuretic actions of vasopressin in the female rat: Variations during the 4 days of the oestrous cycle
38. Central nervous system mediators of vasopressin release
39. Effect of substances influencing brain serotonergic transmission on plasma vasopressin levels in the rat
40. Dopaminergic and cholinergic control of arginine-vasopressin secretion in type I diabetic men
41. The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens
42. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings
43. The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat
44. Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: An in vivo microdialysis study
45. The effects of methylenedioxymethamphetamine (MDMA, "Ecstasy") on monoaminergic neurotransmission in the central nervous system
46. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: Identification of metabolites using an ion trap detector
47. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose
48. Siadh: A serious side effect of psychotropic drugs
49. Vasopressin and other agents affecting the renal conservation of water
50. The effect of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus